Seres Therapeutics (MCRB) Debt to Equity (2019 - 2024)
Seres Therapeutics (MCRB) has disclosed Debt to Equity for 7 consecutive years, with -$1.18 as the latest value for Q2 2024.
- Quarterly Debt to Equity fell 126.42% to -$1.18 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was -$1.18 through Jun 2024, down 126.42% year-over-year, with the annual reading at -$2.26 for FY2023, 148.25% down from the prior year.
- Debt to Equity hit -$1.18 in Q2 2024 for Seres Therapeutics, up from -$1.71 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $4.69 in Q4 2022 to a low of -$6.69 in Q3 2023.
- Historically, Debt to Equity has averaged -$0.0 across 5 years, with a median of $0.14 in 2020.
- Biggest five-year swings in Debt to Equity: skyrocketed 2403.74% in 2022 and later crashed 988.72% in 2023.
- Year by year, Debt to Equity stood at $0.14 in 2020, then skyrocketed by 32.9% to $0.19 in 2021, then surged by 2403.74% to $4.69 in 2022, then crashed by 148.25% to -$2.26 in 2023, then surged by 48.0% to -$1.18 in 2024.
- Business Quant data shows Debt to Equity for MCRB at -$1.18 in Q2 2024, -$1.71 in Q1 2024, and -$2.26 in Q4 2023.